TERN$36.98
Chart
Performance
Key Stats
AI TERN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyTerns Pharmaceuticals is a clinical-stage biopharmaceutical company with a focused pipeline in oncology and metabolic diseases. While its early-stage focus presents higher risk, recent performance and key development catalysts suggest potential for significant upside. The company exhibits strong financial health with substantial cash reserves, which is crucial for its clinical development. However, the lack of revenue and profitability at this stage necessitates a higher risk tolerance from investors. Technical indicators suggest a recent upturn, but the overall market sentiment for biotech can be volatile.
Thematic
Terns Pharmaceuticals operates in the rapidly growing biopharmaceutical sector, targeting areas with significant unmet medical needs such as oncology and metabolic dysfunction-associated steatohepatitis (MASH). The company's focus on small-molecule drug development, particularly its GLP-1R agonist program for obesity and MASH, aligns with strong global health trends and increasing demand for effective treatments in these areas.
Fundamental
Terns Pharmaceuticals, as a clinical-stage company, currently has no revenue and is not profitable. Its financial strength is primarily derived from its substantial cash reserves, which are critical for funding ongoing clinical trials. The company's valuation metrics, such as P/E and P/S ratios, are not applicable or are extremely high due to the absence of current earnings and revenue.
Technical
Terns Pharmaceuticals (TERN) has shown a significant positive price trend over the past month and year-to-date, despite a recent dip. Key moving averages indicate a bullish sentiment, supported by positive short-term momentum. However, some oscillators suggest the stock may be approaching overbought conditions on certain timeframes, warranting attention to potential pullbacks.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 80 |
| Obesity & Metabolic Disease Treatment | 85 |
| Oncology Therapeutics | 75 |
| Drug Development Risk | 60 |
| Competitive Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 0 |
| Valuation | 0 |
| Profitability | 0 |
| Growth | 0 |
| Balance Sheet Health | 85 |
| Balance Sheet Health | 90 |
| Cash Flow | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Trend Analysis | 70 |
| Momentum | 70 |
| Momentum | 85 |
| Support & Resistance | 70 |
| Support & Resistance | 75 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Earnings Surprises
The company has consistently beaten earnings per share (EPS) estimates in recent quarters, with a positive surprise percentage ranging from 7.14% to 22.55% in the last four reported quarters.
Promising Clinical Pipeline
Terns Pharmaceuticals is developing multiple small-molecule product candidates (TERN-701, TERN-501, TERN-601, TERN-800 series) targeting significant areas like oncology, obesity, and metabolic dysfunction-associated steatohepatitis (MASH), with some candidates in Phase 1 and Phase IIa clinical trials.
Bearish Points (8)
Negative Earnings and No Revenue
The company has a Price-to-Sales (P/S) ratio of 0.0 and reported zero revenue for recent periods (2022-2024), which is typical for clinical-stage biotechs but highlights the speculative nature of the investment, with a negative Price-to-Earnings (P/E) ratio (e.g., -7.6 TTM).
Consistent Net Losses
The company has consistently reported significant net losses, with net income of -$88.85 million in Q4 2024 and -$90.21 million in Q4 2023, indicating ongoing operational expenses exceeding revenue.
Calendar
August 2025
4
Next Earnings Date
H: $-0.27
A: $-0.29
L: $-0.31
Profile
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Seasonals
Price Target
20.00 USD
The 39 analysts offering 1 year price forecasts for TERN have a max estimate of 34.00 and a min estimate of 14.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
TERN's largest publicly listed portfolio company, specializing in satellite IoT connectivity. Directly aligned with TERN's core investment strategy.
Weight: 90
Major cloud provider with a comprehensive Azure IoT platform, offering critical infrastructure and services for IoT solutions that TERN's portfolio companies might leverage or compete with.
Weight: 90
Dominant cloud provider via AWS IoT, offering extensive IoT services and solutions for device management, data analytics, and edge computing.
Weight: 88
Designs the architecture for most IoT device processors, fundamental to the hardware layer of the IoT ecosystem.